IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target cancer cells while sparing healthy tissue when both express the CAR-targeted antigen. CAR platform leverages the ability of gamma-delta T cells to selectively target tumor cells supporting the potential of this approach in previously “undruggable” solid-and liquid-tumor targets. Company announces new INB-330 program targeting CD33 in acute myeloid leukemia (AML).
To create an account please click on this link.
If you already have an account, please log in here.